These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 27040140)
1. Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease. Darvesh S Curr Alzheimer Res; 2016; 13(10):1173-7. PubMed ID: 27040140 [TBL] [Abstract][Full Text] [Related]
2. Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease. Macdonald IR; Maxwell SP; Reid GA; Cash MK; DeBay DR; Darvesh S J Alzheimers Dis; 2017; 58(2):491-505. PubMed ID: 28453492 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology. Macdonald IR; Reid GA; Pottie IR; Martin E; Darvesh S J Nucl Med; 2016 Feb; 57(2):297-302. PubMed ID: 26541777 [TBL] [Abstract][Full Text] [Related]
5. Reduced fibrillar β-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model. Darvesh S; Reid GA Chem Biol Interact; 2016 Nov; 259(Pt B):307-312. PubMed ID: 27091549 [TBL] [Abstract][Full Text] [Related]
6. Interaction of exogenous acetylcholinesterase and butyrylcholinesterase with amyloid-β plaques in human brain tissue. Reid GA; Darvesh S Chem Biol Interact; 2024 May; 395():111012. PubMed ID: 38648920 [TBL] [Abstract][Full Text] [Related]
7. Interaction of Exogenous Butyrylcholinesterase with β-Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain. Reid GA; Darvesh S Curr Alzheimer Res; 2021; 18(6):470-481. PubMed ID: 34455970 [TBL] [Abstract][Full Text] [Related]
8. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Wright CI; Geula C; Mesulam MM Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal evaluation of a novel BChE PET tracer as an early Rejc L; Gómez-Vallejo V; Joya A; Moreno O; Egimendia A; Castellnou P; Ríos-Anglada X; Cossío U; Baz Z; Passannante R; Tobalina-Larrea I; Ramos-Cabrer P; Giralt A; Sastre M; Capetillo-Zarate E; Košak U; Knez D; Gobec S; Marder M; Martin A; Llop J Theranostics; 2021; 11(13):6542-6559. PubMed ID: 33995675 [No Abstract] [Full Text] [Related]
13. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could Jasiecki J; Wasąg B Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022 [No Abstract] [Full Text] [Related]
14. Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus. Hamodat H; Cash MK; Fisk JD; Darvesh S Neuropathol Appl Neurobiol; 2017 Dec; 43(7):571-583. PubMed ID: 28644906 [TBL] [Abstract][Full Text] [Related]
15. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169 [TBL] [Abstract][Full Text] [Related]
16. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Duysen EG; Li B; Darvesh S; Lockridge O Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease. Mizukami K; Akatsu H; Abrahamson EE; Mi Z; Ikonomovic MD Neuropathology; 2016 Apr; 36(2):135-45. PubMed ID: 26293308 [TBL] [Abstract][Full Text] [Related]
18. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Karlsson D; Fallarero A; Brunhofer G; Mayer C; Prakash O; Mohan CG; Vuorela P; Erker T Eur J Pharm Sci; 2012 Aug; 47(1):190-205. PubMed ID: 22683890 [TBL] [Abstract][Full Text] [Related]
19. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. Pacheco G; Palacios-Esquivel R; Moss DE J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741 [TBL] [Abstract][Full Text] [Related]
20. The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis. Jasiecki J; Targońska M; Wasąg B Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]